rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Chris Vazquez

Chief Accounting Officer

Company insider

Files Form 4 as: Chief Accounting Officer, Biodesix.

Every Form 4 they filed

In numbers

Trades disclosed
75
Buys
0
Sells
19
Bought
$0
Sold
$18K
Companies
1
Companies where not an officer
0
First trade
24 Jul 2023
Last trade
23 Feb 2026
Last filed
23 Feb 2026

Companies traded

Where they are an officer
BDSX BiodesixOfficer · Diagnostics & Labs · last 23 Feb 20260 buys · 19 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
23 Feb 2026filed 23 Feb 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Sold$2,696211 at $12.78filing
23 Feb 2026filed 23 Feb 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Sold$2,697211 at $12.78filing
20 Feb 2026filed 23 Feb 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Code M—563filing
20 Feb 2026filed 23 Feb 2026BDSX Biodesixoption or derivative · Diagnostics & LabsSEC FORM 4 Code M—563 at $0.00filing
20 Feb 2026filed 23 Feb 2026BDSX Biodesixoption or derivative · Diagnostics & LabsSEC FORM 4 Code M—563 at $0.00filing
20 Feb 2026filed 23 Feb 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Code M—563filing
10 Feb 2026filed 11 Feb 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Sold$1,018101 at $10.08filing
10 Feb 2026filed 11 Feb 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Sold$1,018101 at $10.08filing
9 Feb 2026filed 11 Feb 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Code M—263filing
9 Feb 2026filed 11 Feb 2026BDSX Biodesixoption or derivative · Diagnostics & LabsSEC FORM 4 Code M—28 at $0.00filing
9 Feb 2026filed 11 Feb 2026BDSX Biodesixoption or derivative · Diagnostics & LabsSEC FORM 4 Code M—28 at $0.00filing
9 Feb 2026filed 11 Feb 2026BDSX Biodesixoption or derivative · Diagnostics & LabsSEC FORM 4 Code M—235 at $0.00filing
9 Feb 2026filed 11 Feb 2026BDSX Biodesixoption or derivative · Diagnostics & LabsSEC FORM 4 Code M—235 at $0.00filing
9 Feb 2026filed 11 Feb 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Code M—263filing
16 Jan 2026filed 20 Jan 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Sold$67683 at $8.15filing
16 Jan 2026filed 20 Jan 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Sold$67683 at $8.15filing
15 Jan 2026filed 20 Jan 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Code M—219filing
15 Jan 2026filed 20 Jan 2026BDSX Biodesixoption or derivative · Diagnostics & LabsSEC FORM 4 Code M—219 at $0.00filing
15 Jan 2026filed 20 Jan 2026BDSX Biodesixoption or derivative · Diagnostics & LabsSEC FORM 4 Code M—219 at $0.00filing
15 Jan 2026filed 20 Jan 2026BDSX BiodesixDiagnostics & LabsSEC FORM 4 Code M—219filing

Sectors

Health Care19

Buys in green, sells in red, by the company’s sector.

Related people

John PatienceDirector and Other role · Director and Other at Biodesix, filing Form 4 there in the last year
Jack W. Schuler10% owner and Other role · 10% owner and Other at Biodesix, filing Form 4 there in the last year
Scott HuttonPresident & CEO · President & CEO at Biodesix, filing Form 4 there in the last year
Robin Harper CowieCFO, Sec'y & Treasurer · CFO, Sec'y & Treasurer at Biodesix, filing Form 4 there in the last year
Gary Anthony PestanoChief Development Officer · Chief Development Officer at Biodesix, filing Form 4 there in the last year